Analysis
Enveda Biosciences, the Boulder, Colorado-based drug-discovery company, raised a $311 million Series E on Wednesday led by Catalio Capital Management, with Surveyor Capital, T. Rowe Price and Lux Capital among the participants, valuing the company at roughly $2 billion, according to Tech Startups' funding roundup.
The Platform
Founded in 2019 by CEO Viswa Colluru and mass-spectrometry researcher Pieter Dorrestein, Enveda combines metabolomics -- the large-scale study of small molecules inside cells -- with machine learning to decode the chemistry hidden in plants, microbes and other natural sources at a speed traditional natural-products chemistry can't match. The company's lead internal program, ENV-294, targets inflammatory conditions including atopic dermatitis and has advanced into Phase 1 clinical trials, giving Enveda an actual clinical data point rather than only a discovery-stage promise.
Funding History And Competitive Field
Enveda previously raised a $130 million round in 2024 and a $150 million Series D aimed at immune and obesity indications, becoming a unicorn in 2025 before this Series E roughly doubles that valuation. The company competes for AI-drug-discovery capital and validation against firms like Recursion Pharmaceuticals and Isomorphic Labs on the platform side, while its actual drug candidates will eventually compete against established players in inflammatory disease such as Sanofi and Regeneron.
The round lands the same week as Basecamp Research's $140 million Series C and Anthropic's own life-sciences lab announcement, part of a broader capital wave betting that AI-driven biological discovery platforms can compress the traditionally decade-long, billion-dollar drug-discovery timeline. None of these platforms has yet produced an FDA-approved drug from an AI-discovered natural compound, and Enveda's own most advanced program is still in early-stage Phase 1 trials -- a reminder that a doubled valuation reflects investor conviction in the platform's discovery engine, not yet proof that engine reliably produces approved medicines.
For biotech-focused GPs, Enveda's T. Rowe Price participation is worth noting: it's a public-markets crossover investor signaling this round is being priced with a future IPO in mind, not purely as a private growth round.